Literature DB >> 11152833

Hemostatic state and atrial fibrillation (the Framingham Offspring Study).

D Feng1, R B D'Agostino, H Silbershatz, I Lipinska, J Massaro, D Levy, E J Benjamin, P A Wolf, G H Tofler.   

Abstract

Atrial fibrillation (AF) is strongly associated with thromboembolic complications, although the mechanism for the increased risk has not been fully explained. To determine whether AF might be associated with a hypercoagulable state, we studied hemostatic factors in subjects with or without AF in the Framingham Heart Study. In 3,577 subjects, we measured fibrinogen, von Willebrand factor antigen, tissue plasminogen activator (tPA) antigen, and plasminogen activator inhibitor-1 antigen. Forty-seven subjects had AF at the index clinic examination and 15 had AF on a prior examination, but not on the current examination. Before matching, the 47 subjects with prevalent AF had higher levels of fibrinogen, von Willebrand factor, and tPA antigen than those without AF, all p < or =0.03. Compared with 167 referent subjects matched for age, sex, and other risk factors, those with AF had higher tPA antigen levels than those without AF, 1 1.8 +/- 4.0 ng/ml versus 10.5 +/- 3.9 ng/ml (p = 0.04). However, when further stratified according to their cardiovascular disease status, the differences in hemostatic factors were no longer significant. We conclude that the prothrombotic profile associated with AF was explained by the risk factors of the subjects and the presence of cardiovascular disease. Nonetheless, the hemostatic changes may contribute toward the propensity for thromboembolic complications in AF. Further prospective studies are needed to evaluate whether measurement of these and other hemostatic factors will identify patients with AF who are at increased risk for thromboembolic complications, and who may therefore benefit from more intensive therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11152833     DOI: 10.1016/s0002-9149(00)01310-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  17 in total

Review 1.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

2.  Pharmacologic strategies for the prevention of stroke in patients with atrial fibrillation.

Authors:  Greg Flaker; Richard Weachter
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-10

3.  Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study.

Authors:  Alvaro Alonso; Weihong Tang; Sunil K Agarwal; Elsayed Z Soliman; Alanna M Chamberlain; Aaron R Folsom
Journal:  Int J Cardiol       Date:  2010-10-20       Impact factor: 4.164

4.  Outcomes in ambulatory chronic systolic and diastolic heart failure: a propensity score analysis.

Authors:  Ali Ahmed; Gilbert J Perry; Jerome L Fleg; Thomas E Love; David C Goff; Dalane W Kitzman
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

5.  Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation.

Authors:  Albert Yuh-Jer Shen; Wansu Chen; Janis F Yao; Somjot S Brar; Xunzhang Wang; Alan S Go
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

6.  Haemostatic activity in patients with atrial fibrillation treated with low-molecular-weight heparin before and after electrical cardioversion.

Authors:  Elisabeth L Zeuthen; Jens Flensted Lassen; Steen E Husted
Journal:  J Thromb Thrombolysis       Date:  2004-06       Impact factor: 2.300

Review 7.  Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal.

Authors:  Fabio Marsico; Milena Cecere; Antonio Parente; Stefania Paolillo; Fabiana de Martino; Santo Dellegrottaglie; Bruno Trimarco; Pasquale Perrone Filardi
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

8.  Impaired fibrinolytic capacity in rheumatic mitral stenosis with or without atrial fibrillation and nonrheumatic atrial fibrillation.

Authors:  Enver Atalar; Ferhan Ozmen; Ibrahim Haznedaroğlu; Necla Ozer; Serdar Aksöyek; Kenan Ovünç; Nasih Nazli; Serafettin Kirazli; Sirri Kes
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

Review 9.  Von Willebrand Factor Plasma Levels Variability In Nonvalvular Atrial Fibrillation.

Authors:  Gerardo Muñoz Cortés; Martha Eva Viveros Sandoval; Carlos Arturo Areán Martínez; Helios Eduardo Vega Gómez; Sandra Edith López Castañeda; Anel Gómez García
Journal:  J Atr Fibrillation       Date:  2014-12-31

10.  Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Authors:  Alan S Go; Margaret C Fang; Natalia Udaltsova; Yuchiao Chang; Niela K Pomernacki; Leila Borowsky; Daniel E Singer
Journal:  Circulation       Date:  2009-03-02       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.